List of Syros Pharmaceuticals patents

Patents where

Current Assignee

Name

Syros Pharmaceuticals

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 10059690 Inhibitors of cyclin-dependent kinase 7 (CDK7)	Patent 10059690 was granted and assigned to Syros Pharmaceuticals on August, 2018 by the United States Patent and Trademark Office.	Syros Pharmaceuticals	Syros Pharmaceuticals	United States Patent and Trademark Office	10059690	August 28, 2018
‌ US Patent 10519135 Inhibitors of cyclin-dependent kinase 7 (CDK7)	Patent 10519135 was granted and assigned to Syros Pharmaceuticals on December, 2019 by the United States Patent and Trademark Office.	Syros Pharmaceuticals	Syros Pharmaceuticals	United States Patent and Trademark Office	10519135	December 31, 2019
‌ US Patent 10106526 Inhibitors of cyclin-dependent kinase 7 (CDK7)	Patent 10106526 was granted and assigned to Syros Pharmaceuticals on October, 2018 by the United States Patent and Trademark Office.	Syros Pharmaceuticals	Syros Pharmaceuticals	United States Patent and Trademark Office	10106526	October 23, 2018
‌ US Patent 11311542 Inhibitors of cyclin dependent kinase 7 (CDK7)	Patent 11311542 was granted and assigned to Syros Pharmaceuticals on April, 2022 by the United States Patent and Trademark Office.	Syros Pharmaceuticals	Syros Pharmaceuticals	United States Patent and Trademark Office	11311542	April 26, 2022
‌ US Patent 11447831 Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists		Syros Pharmaceuticals	Syros Pharmaceuticals	United States Patent and Trademark Office	11447831	September 20, 2022
‌ US Patent 11053552 Methods of stratifying patients for treatment with retinoic acid receptor-α agonists	Patent 11053552 was granted and assigned to Syros Pharmaceuticals on July, 2021 by the United States Patent and Trademark Office.	Syros Pharmaceuticals	Syros Pharmaceuticals	United States Patent and Trademark Office	11053552	July 6, 2021
‌ US Patent 10308648 Inhibitors of cyclin-dependent kinase 7 (CDK7)	Patent 10308648 was granted and assigned to Syros Pharmaceuticals on June, 2019 by the United States Patent and Trademark Office.	Syros Pharmaceuticals	Syros Pharmaceuticals	United States Patent and Trademark Office	10308648	June 4, 2019
‌ US Patent 10240210 Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists	Patent 10240210 was granted and assigned to Syros Pharmaceuticals on March, 2019 by the United States Patent and Trademark Office.	Syros Pharmaceuticals	Syros Pharmaceuticals	United States Patent and Trademark Office	10240210	March 26, 2019
‌ US Patent 10167518 Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists	Patent 10167518 was granted and assigned to Syros Pharmaceuticals on January, 2019 by the United States Patent and Trademark Office.	Syros Pharmaceuticals	Syros Pharmaceuticals	United States Patent and Trademark Office	10167518	January 1, 2019
‌ US Patent 9845508 Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists	Patent 9845508 was granted and assigned to Syros Pharmaceuticals on December, 2017 by the United States Patent and Trademark Office.		Syros Pharmaceuticals	United States Patent and Trademark Office	9845508	December 19, 2017
‌ US Patent 10336760 Inhibitors of cyclin-dependent kinase 7 (CDK7)	Patent 10336760 was granted and assigned to Syros Pharmaceuticals on July, 2019 by the United States Patent and Trademark Office.	Syros Pharmaceuticals	Syros Pharmaceuticals	United States Patent and Trademark Office	10336760	July 2, 2019
‌ US Patent 10697025 Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists		Syros Pharmaceuticals	Syros Pharmaceuticals	United States Patent and Trademark Office	10697025	June 30, 2020
‌ US Patent 10738067 Inhibitors of cyclin-dependent kinase 7 (CDK7)		Syros Pharmaceuticals	Syros Pharmaceuticals	United States Patent and Trademark Office	10738067	August 11, 2020
‌ US Patent 10865206 Inhibitors of cyclin-dependent kinase 7 (CDK7)		Syros Pharmaceuticals	Syros Pharmaceuticals	United States Patent and Trademark Office	10865206	December 15, 2020
‌ US Patent 11274103 Compounds for the modulation of MYC activity	Patent 11274103 was granted and assigned to Syros Pharmaceuticals on March, 2022 by the United States Patent and Trademark Office.	Syros Pharmaceuticals	Syros Pharmaceuticals	United States Patent and Trademark Office	11274103	March 15, 2022
‌ US Patent 10787444 Compounds for the modulation of myc activity		Syros Pharmaceuticals	Syros Pharmaceuticals	United States Patent and Trademark Office	10787444	September 29, 2020
‌ US Patent 11040981 Pyrrolotriazine compounds and methods of inhibiting TAM kinases	Patent 11040981 was granted and assigned to Syros Pharmaceuticals on June, 2021 by the United States Patent and Trademark Office.	Syros Pharmaceuticals	Syros Pharmaceuticals	United States Patent and Trademark Office	11040981	June 22, 2021
‌ US Patent 11124527 Compounds for the modulation of Myc activity	Patent 11124527 was granted and assigned to Syros Pharmaceuticals on September, 2021 by the United States Patent and Trademark Office.	Syros Pharmaceuticals	Syros Pharmaceuticals	United States Patent and Trademark Office	11124527	September 21, 2021
‌ US Patent 11083728 Compositions of cyclin dependent kinase 7 (CDK7) inhibitor	Patent 11083728 was granted and assigned to Syros Pharmaceuticals on August, 2021 by the United States Patent and Trademark Office.	Syros Pharmaceuticals	Syros Pharmaceuticals	United States Patent and Trademark Office	11083728	August 10, 2021
‌ US Patent 11918592 Inhibitors of cyclin dependent kinase 7 (CDK7)	Patent 11918592 was granted and assigned to Syros Pharmaceuticals on March, 2024 by the United States Patent and Trademark Office.	Syros Pharmaceuticals	Syros Pharmaceuticals	United States Patent and Trademark Office	11918592	March 5, 2024
‌ US Patent 11753418 Compounds for the modulation of Myc activity	Patent 11753418 was granted and assigned to Syros Pharmaceuticals on September, 2023 by the United States Patent and Trademark Office.	Syros Pharmaceuticals	Syros Pharmaceuticals	United States Patent and Trademark Office	11753418	September 12, 2023

21 results

0 selected

21 results

0 selected